{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-23-000135","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2023-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.559170+00:00","generated_at":"2026-06-09T05:40:40.117441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M","bullets":["Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).","Consumables revenue $16.9M (record; +5% YoY) with Revio consumables surpassing Sequel II/IIe.","GAAP net loss $66.9M ($0.26/shr) vs $77.0M ($0.34/shr) prior year; Non-GAAP net loss $67.9M ($0.27).","Gross margin 32% vs 42% prior year; non-GAAP gross margin also 32%.","Cash and investments $767.8M; launched leasing program, first Onso shipments, and new WGS variant pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-23-000135","json":"https://secwatch.observer/filing/0001299130-23-000135.json","markdown":"https://secwatch.observer/filing/0001299130-23-000135.md","text":"https://secwatch.observer/filing/0001299130-23-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/0001299130-23-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/pacb-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:40:40.117441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53cb996e9b9b1991b2ca73a18e07fefe1da94e0f","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended September 30, 2023 results: revenue $55.7 million, net income Net loss for the third quarter of 2023 was $66.9 million, EPS $0.26.","evidence_excerpt":"PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results • Revenue of $55.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000135/0001299130-23-000135-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$55.7 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $66.9 million"},{"label":"EPS","value":"$0.26"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}